Skip to main content

UBS Group AG

Position in NTLA — Intellia Therapeutics, Inc.

CIK 1610520 ZURICH, V8

Position in NTLA

as of Mar 31, 2026 · filed May 5, 2026
Position Value
$34,479,209
+$26,751,839 QoQ
Shares Held
2,689,486
+212.9% QoQ
Ownership
1.92%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
not a current holder
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 96% Shared 0% None 4%

Common Shares in NTLA Over Time

Shares Held

Position Value (USD)

Derivatives in NTLA

reported options exposure · as of Mar 31, 2026
CallValue
$7,291,657
CallShares
568,772
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

UBS Group AG holds $8,307,109,707 across 562 Biotechnology names. NTLA ranks #51 (0.4% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in NTLA

Export CSV
31 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $7,291,657 568,772
2026-03-31 $34,479,209 2,689,486
2025-12-31 $3,399,874 378,184
2025-12-31 $7,727,370 859,552
2025-09-30 $19,138,370 1,108,186
2025-09-30 $8,563,778 495,876
2025-06-30 $8,262,588 880,873
2025-06-30 $2,257,850 240,709
2025-03-31 $8,011,574 1,126,804
2024-12-31 $20,309,012 1,741,768
2024-09-30 $5,721,776 278,432
2024-09-30 $383,216 18,648
2024-06-30 $5,719,229 255,551
2024-03-31 $9,121,930 331,586
2023-12-31 $8,370,235 274,524
2023-09-30 $3,921,101 124,007
2023-06-30 $5,499,957 134,869
2023-03-31 $3,330,967 89,374
2022-12-31 $6,336,406 181,611
2022-09-30 $2,740,248 48,968
2022-06-30 $2,428,267 46,914
2022-03-31 $2,470,780 34,000
2022-03-31 $7,207,337 99,179
2021-12-31 $13,615,099 115,148
2021-09-30 $8,646,503 64,454
2021-06-30 $8,000,782 49,415
2021-03-31 $4,182,168 52,111
2020-12-31 $6,851,624 125,949
2020-09-30 $1,501,655 75,536
2020-06-30 $1,802,254 85,740
2020-03-31 $998,811 81,669